The FDA has tentatively scheduled a meeting of the Orthopaedic and Rehabilitation Devices Panel to review Cartiva's premarket approval application for its Cartiva Synthetic Cartilage Implant.
Here are four points:
1. The meeting is slated to take place on April 20.
2. The implant is intended for the treatment of osteoarthritis at the base of the big toe.
3. The FDA recently completed a five-day inspection of Cartiva's Alpharetta, Ga., facility and reported no issues.
4. Cartiva is a developer of products for the treatment of cartilage injuries, osteoarthritis and other musculoskeletal conditions.